Literature DB >> 17293390

Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.

S Di Palma1, N Collins, C Faulkes, B Ping, G Ferns, B Haagsma, G Layer, M W Kissin, M G Cook.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17293390      PMCID： PMC1972421          DOI： 10.1136/jcp.2006.043356

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  14 in total

1.  Best Practice No 176: Updated recommendations for HER2 testing in the UK.

Authors:  I O Ellis; J Bartlett; M Dowsett; S Humphreys; B Jasani; K Miller; S E Pinder; A Rhodes; R Walker
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

2.  Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.

Authors:  Yun Gong; Michael Gilcrease; Nour Sneige
Journal:  Mod Pathol       Date:  2005-08       Impact factor: 7.842

3.  Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.

Authors:  Cornelia Hauser-Kronberger; Nadia Dandachi
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

4.  Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.

Authors:  M Laakso; M Tanner; J Isola
Journal:  J Pathol       Date:  2006-09       Impact factor: 7.996

5.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

Authors:  G Pauletti; S Dandekar; H Rong; L Ramos; H Peng; R Seshadri; D J Slamon
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

6.  Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.

Authors:  Wedad M Hanna; Kevin Kwok
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

7.  Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma.

Authors:  Nadia Dandachi; Otto Dietze; Cornelia Hauser-Kronberger
Journal:  Lab Invest       Date:  2002-08       Impact factor: 5.662

8.  Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.

Authors:  Jorma Isola; Minna Tanner; Amanda Forsyth; Timothy G Cooke; Amanda D Watters; John M S Bartlett
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

9.  Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?

Authors:  Torill Sauer; Gro Wiedswang; Ghania Boudjema; Hanne Christensen; Rolf Karesen
Journal:  APMIS       Date:  2003-03       Impact factor: 3.205

10.  HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

Authors:  Elena B Elkin; Milton C Weinstein; Eric P Winer; Karen M Kuntz; Stuart J Schnitt; Jane C Weeks
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544
View more
  10 in total

1.  Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.

Authors:  Sabine Riethdorf; Bernhard Hoegel; Birgit John; German Ott; Peter Fritz; Susanne Thon; Thomas Loening; Klaus Pantel
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-16       Impact factor: 4.553

Review 2.  Progress on deep learning in digital pathology of breast cancer: a narrative review.

Authors:  Jingjin Zhu; Mei Liu; Xiru Li
Journal:  Gland Surg       Date:  2022-04

3.  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.

Authors:  Tomás García-Caballero; Dorthe Grabau; Andrew R Green; John Gregory; Arno Schad; Elke Kohlwes; Ian O Ellis; Sarah Watts; Jens Mollerup
Journal:  Histopathology       Date:  2010-03       Impact factor: 5.087

Review 4.  Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.

Authors:  Aaron M Gruver; Ziad Peerwani; Raymond R Tubbs
Journal:  J Clin Pathol       Date:  2010-03       Impact factor: 3.411

5.  Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.

Authors:  Antonino Carbone; Gerardo Botti; Annunziata Gloghini; Gianni Simone; Mauro Truini; Maria Pia Curcio; Patrizia Gasparini; Anita Mangia; Tiziana Perin; Sandra Salvi; Adele Testi; Paolo Verderio
Journal:  J Mol Diagn       Date:  2008-10-02       Impact factor: 5.568

6.  Evaluating HER2 Gene Amplification Using Chromogenic In Situ Hybridization (CISH) Method In Comparison To Immunohistochemistry Method in Breast Carcinoma.

Authors:  Hadi Atabati; Amir Raoofi; Abdollah Amini; Reza Masteri Farahani
Journal:  Open Access Maced J Med Sci       Date:  2018-11-20

Review 7.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Authors:  Jiani Wang; Binghe Xu
Journal:  Signal Transduct Target Ther       Date:  2019-09-13

8.  Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.

Authors:  Fabíola E Rosa; Sara M Silveira; Cássia G T Silveira; Nádia A Bérgamo; Francisco A Moraes Neto; Maria A C Domingues; Fernando A Soares; José R F Caldeira; Silvia R Rogatto
Journal:  BMC Cancer       Date:  2009-03-23       Impact factor: 4.430

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

Review 10.  Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas.

Authors:  F E Rosa; R M Santos; S R Rogatto; M A C Domingues
Journal:  Braz J Med Biol Res       Date:  2013-03-19       Impact factor: 2.590
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.